Status:
COMPLETED
The Efficacy of Nutrilite All-plant Protein Booster to Improve Sarcopenia and Osteoarthritis in Middle-aged and Elderly People
Lead Sponsor:
Amway (China) R&D Center
Conditions:
Osteoarthritis
Sarcopenia
Eligibility:
All Genders
50-70 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn whether Amway Nutrilite All-plant protein booster prototype product (test product) will improve sarcopenia (SA) and osteoarthritis (OA) in middle-aged and e...
Eligibility Criteria
Inclusion
- Be age 50 to 70 years, female and male
- Participants will be required to have mild to moderately OA \& SA evaluated by Kellgren-Lawrence I-II and SARC-Cal, respectively
- Participants need to be competent i.e., able to understand what is to take place and able to provide a free decision on agreeing to the activity/taking part on the study on this
- Participants must be able to read and understand study instructions and any other relevant study documents
- Willing to following the lifestyle restrictions as detailed in the Information Sheet for study
- Will to give written informed consent
Exclusion
- Have a fever currently, or for 24 hours before enrollment
- Currently participating in another clinical study
- Have taken other protein powder products and dietary supplements or medicines containing peptides or hyaluronic acid within the past 6 months (subject to product instructions)
- Individuals receiving medical treatment that, in the opinion of the Principal Investigator or Study Physician, may interfere with test results
- The participant is an employee of Amway or SPRIM Medical
- Subject who is in the treatment of gastrointestinal diseases
- Subject with abnormal liver function tests (alanine aminotransferase and aspartate aminotransferase), kidney function tests (blood urea nitrogen and creatinine), blood routine, urine routine, fecal occult blood test, or electrocardiogram.
- Subjects have any of the following medical history or have been clinically examined to have the following diseases that may affect the evaluation of the test effect: obvious gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases
Key Trial Info
Start Date :
July 8 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 2 2025
Estimated Enrollment :
139 Patients enrolled
Trial Details
Trial ID
NCT06499012
Start Date
July 8 2025
End Date
October 2 2025
Last Update
November 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jinhua Wenrong Hospital
Jinhua, Zhejiang, China